190 related articles for article (PubMed ID: 30682180)
1. Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
Shili-Masmoudi S; Sogni P; de Ledinghen V; Esterle L; Valantin MA; Poizot-Martin I; Simon A; Rosenthal E; Lacombe K; Pialoux G; Bouchaud O; Gervais-Hasenknoff A; Goujard C; Piroth L; Zucman D; Dominguez S; Raffi F; Alric L; Bani-Sadr F; Lascoux-Combe C; Garipuy D; Miailhes P; Vittecoq D; Duvivier C; Aumaître H; Neau D; Morlat P; Dabis F; Salmon D; Wittkop L;
PLoS One; 2019; 14(1):e0211286. PubMed ID: 30682180
[TBL] [Abstract][Full Text] [Related]
2. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
3. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
4. Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study).
Barré T; Protopopescu C; Bani-Sadr F; Piroth L; Rojas Rojas T; Salmon-Ceron D; Wittkop L; Esterle L; Sogni P; Lacombe K; Chas J; Zaegel O; Chaix ML; Miailhes P; Serfaty L; Marcellin F; Carrieri MP;
Hepatology; 2020 Apr; 71(4):1182-1197. PubMed ID: 31466125
[TBL] [Abstract][Full Text] [Related]
5. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
7. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis.
John BV; Dang Y; Kaplan DE; Jou JH; Taddei TH; Spector SA; Martin P; Bastaich DR; Chao HH; Dahman B
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):778-788.e7. PubMed ID: 38061410
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response.
Fernandes FF; Piedade J; Guimaraes L; Nunes EP; Chaves U; Goldenzon RV; Cardoso SW; Duarte J; Grinsztejn B; Veloso VG; Pereira G; Perazzo H
J Gastroenterol Hepatol; 2019 Dec; 34(12):2187-2195. PubMed ID: 31062880
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
11. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].
Michel L; Lions C; Winnock M; Lang JP; Loko MA; Rosenthal E; Marchou B; Valantin MA; Morlat P; Roux P; Sogni P; Spire B; Poizot-Martin I; Lacombe K; Lascoux-Combe C; Duvivier C; Neau D; Dabis F; Salmon-Ceron D; Carrieri MP;
HIV Med; 2016 Nov; 17(10):758-765. PubMed ID: 27187027
[TBL] [Abstract][Full Text] [Related]
12. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
13. Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.
Macías J; Camacho A; Von Wichmann MA; López-Cortés LF; Ortega E; Tural C; Ríos MJ; Merino D; Téllez F; Márquez M; Mancebo M; Pineda JA
AIDS; 2013 Oct; 27(16):2541-9. PubMed ID: 23736148
[TBL] [Abstract][Full Text] [Related]
14. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.
Macías J; del Valle J; Rivero A; Mira JA; Camacho A; Merchante N; Pérez-Camacho I; Neukam K; Rivero-Juárez A; Mata R; Torre-Cisneros J; Pineda JA;
J Antimicrob Chemother; 2010 Oct; 65(10):2204-11. PubMed ID: 20656678
[TBL] [Abstract][Full Text] [Related]
15. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes.
Piedade J; Pereira G; Guimarães L; Duarte J; Victor L; Baldin C; Inacio C; Santos R; Chaves Ú; Nunes EP; Grinsztejn B; Veloso VG; Fernandes F; Perazzo H
Sci Rep; 2021 Jun; 11(1):11681. PubMed ID: 34083617
[TBL] [Abstract][Full Text] [Related]
16. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.
Chalouni M; Wittkop L; Bani-Sadr F; Lacombe K; Esterle L; Gilbert C; Miailhes P; Zucman D; Valantin MA; Brégigeon-Ronot S; Morlat P; Billaud E; Piroth L; Naqvi A; Sogni P; Salmon D;
HIV Med; 2021 Oct; 22(9):791-804. PubMed ID: 34212476
[TBL] [Abstract][Full Text] [Related]
17. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
Semmler G; Alonso López S; Pons M; Lens S; Dajti E; Griemsmann M; Zanetto A; Burghart L; Hametner-Schreil S; Hartl L; Manzano M; Rodriguez-Tajes S; Zanaga P; Schwarz M; Gutierrez ML; Jachs M; Pocurull A; Polo B; Ecker D; Mateos B; Izquierdo S; Real Y; Ahumada A; Bauer DJM; Mauz JB; Casanova-Cabral M; Gschwantler M; Russo FP; Azzaroli F; Maasoumy B; Reiberger T; Forns X; Genesca J; Bañares R; Mandorfer M;
J Hepatol; 2024 Jul; 81(1):76-83. PubMed ID: 38521170
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.
Carrieri MP; Protopopescu C; Marcellin F; Rosellini S; Wittkop L; Esterle L; Zucman D; Raffi F; Rosenthal E; Poizot-Martin I; Salmon-Ceron D; Dabis F; Spire B;
J Hepatol; 2017 Dec; 67(6):1157-1167. PubMed ID: 28942916
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C.
van Santen DK; Agius PA; Sasadeusz J; Fairley CK; Sievert W; Gane E; Iser D; O'Reilly M; Medland NA; Moore R; Hellard ME; Hoy JF; Doyle JS;
J Acquir Immune Defic Syndr; 2020 Dec; 85(5):e81-e89. PubMed ID: 32842055
[TBL] [Abstract][Full Text] [Related]
20. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
